Abstract
Male breast cancer (MBC) is a rare and special male malignant tumor whose morbidity is much lower than that of female breast cancer (FBC) due to the different physiological factors. There have been multiple well-meaning attempts to show that, after adjusting for stage and age, the prognosis of MBC is similar to that of FBC, but there are vast differences in the expression of hormone receptors, HER-2, Ki-67 and BCL2. With developments in molecular biology and the transcriptosomic landscape of breast malignancy, there will be an increase in our knowledge of the molecular differences between breast cancer in females and males. For MBC patients, these differences may be of great importance for the prognosis and systemic therapy. Summing up the relevant literatures in China and abroad in recent years, this paper provides an overview of the molecular biology research progress of MBC, in order to strengthen the understanding and attention of clinicians and patients for MBC. Key words: Breast neoplasms, male; Neoplasm staging; Tumor markers, biological
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
